Efficacy and safety of a single intra-articular injection of 6 ml Hylan G-F 20 compared to placebo in Chinese patients with symptomatic knee osteoarthritis

Table 3 Mean change in 7-day average WOMAC A1 from baseline over 26 weeks

	Placebo (N = 220)	Single 6 ml Hylan G-F 20 injection (N = 218)
Baseline
Number	220	216
Mean (SD)	5.34 (1.03)	5.48 (1.07)
Median	5.14	5.36
Min; Max	3.7; 8.0	3.7; 8.3
Change from baseline over 26 weeks
LS Mean (SE)	−2.275 (0.108)	−2.176 (0.106)
LS Mean Difference (SE) vs. Placebo		0.099 (0.135)
95% CI		(−0.166 to 0.364)
P-value		0.4637

Least-square (LS) means, standard errors (SE) and p-value are taken from repeated measures of Covariance analysis. The model includes treatment groups (Single 6 ml Hylan G-F 20 injection and placebo), site, visit and visit by treatment interaction, as well as the baseline 7-day average WOMAC A1 score as a covariate. Included are patients who have measurements at baseline and at least one post-baseline value

ISSN: 1471-2474